Prima BioMed (IMMP) News Today $1.71 +0.01 (+0.59%) As of 07/3/2025 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Immutep (NASDAQ:IMMP) Cut to Sell at Wall Street ZenJune 14, 2025 | marketbeat.comImmutep (NASDAQ:IMMP) Cut to "Sell" at Wall Street ZenMay 31, 2025 | marketbeat.comImmutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma TrialMay 28, 2025 | tipranks.comImmutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | finanznachrichten.deImmutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue SarcomaMay 27, 2025 | globenewswire.comImmutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma TrialMay 25, 2025 | tipranks.comImmutep (NASDAQ:IMMP) Upgraded by Wall Street Zen to "Hold" RatingMay 24, 2025 | marketbeat.comImmutep reports promising lung cancer trial resultsMay 16, 2025 | investing.comImmutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15, 2025 | finance.yahoo.comIs Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comImmutep’s Efti Combination Shows Promising Results in Lung Cancer TrialMay 14, 2025 | tipranks.comImmutep Limited: Surging On Positive Head And Neck DataMay 8, 2025 | seekingalpha.comImmutep (NASDAQ:IMMP) Stock Crosses Below 50 Day Moving Average - Time to Sell?May 5, 2025 | marketbeat.comImmutep’s Efti Shows Promising Results in Head and Neck Cancer TrialMay 4, 2025 | tipranks.comImmutep Quarterly Activities Report Q3 FY25April 29, 2025 | finance.yahoo.comImmutep Limited Reports First Patient Dosed in TACTI-004 Phase III Lung Cancer Trial and Updates on Clinical ProgressApril 29, 2025 | quiverquant.comQImmutep Advances Cancer Trials with Promising DevelopmentsApril 28, 2025 | tipranks.comImmutep (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average - Here's WhyApril 27, 2025 | marketbeat.comImmutep to Participate in Upcoming Investor ConferencesApril 2, 2025 | globenewswire.comImmutep (NASDAQ:IMMP) Stock Crosses Below Fifty Day Moving Average - Here's What HappenedApril 2, 2025 | marketbeat.comImmutep to Engage in Key Investor ConferencesApril 1, 2025 | tipranks.comImmutep: A Small Company With A Pipeline Resembling Big PharmaMarch 31, 2025 | seekingalpha.comFirst Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerMarch 25, 2025 | finance.yahoo.comImmutep (NASDAQ:IMMP) Stock Passes Below Fifty Day Moving Average - Time to Sell?March 23, 2025 | marketbeat.comImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025March 20, 2025 | markets.businessinsider.comImmutep to Present Pivotal Lung Cancer Trial at ELCC 2025March 19, 2025 | tipranks.comImmutep Limited (IMMP): Among the Best Australian Stocks to Buy According to BillionairesMarch 10, 2025 | msn.comImmutep Reports Increased Revenue Amid Growing R&D CostsMarch 2, 2025 | tipranks.comImmutep (NASDAQ:IMMP) Shares Pass Below Fifty Day Moving Average - What's Next?February 25, 2025 | marketbeat.comIs Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?February 11, 2025 | insidermonkey.comImmutep (NASDAQ:IMMP) Stock Passes Below 50-Day Moving Average - Time to Sell?February 5, 2025 | marketbeat.comImmutep reports quarterly activities and financialsFebruary 4, 2025 | msn.comImmutep Advances to Phase III with Key Approvals and Promising Trial ResultsFebruary 3, 2025 | tipranks.comImmutep Limited: Immutep Quarterly Activities Report Q2 FY25January 31, 2025 | finanznachrichten.deImmutep promotes Christian Mueller to CDO, CMO Florian Vogl to departJanuary 31, 2025 | markets.businessinsider.comImmutep reports Q2 cash receipts from customers A$8,000January 31, 2025 | markets.businessinsider.comImmutep Limited Announces Transition to Phase III with Regulatory Approval for TACTI-004 Trial in Non-Small Cell Lung CancerJanuary 31, 2025 | quiverquant.comQImmutep Quarterly Activities Report Q2 FY25January 31, 2025 | globenewswire.comIs Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?January 31, 2025 | insidermonkey.comImmutep Limited: Continuing To Make The Case For EftilagimodJanuary 28, 2025 | seekingalpha.comPatient Enrolment Completed for EFTISARC-NEO Phase II TrialJanuary 22, 2025 | markets.businessinsider.comImmutep (NASDAQ:IMMP) Stock Passes Below Fifty Day Moving Average - What's Next?January 22, 2025 | marketbeat.comImmutep Completes Patient Enrolment for Key Phase II Cancer TrialJanuary 21, 2025 | tipranks.comImmutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the companyJanuary 16, 2025 | au.finance.yahoo.comImmutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?January 14, 2025 | marketbeat.comImmutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average - What's Next?December 26, 2024 | marketbeat.comImmutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761December 17, 2024 | globenewswire.comImmutep, Monash University announce publication on human LAG-3December 17, 2024 | markets.businessinsider.comImmutep (NASDAQ:IMMP) Shares Down 4.6% - Here's What HappenedDecember 16, 2024 | marketbeat.comImmutep Reveals Promising Data for IMP761 TrialDecember 16, 2024 | tipranks.com Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMP Media Mentions By Week IMMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMP News Sentiment▼0.000.58▲Average Medical News Sentiment IMMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMP Articles This Week▼01▲IMMP Articles Average Week Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Spyre Therapeutics News Mineralys Therapeutics News Avadel Pharmaceuticals News Pharvaris News Nurix Therapeutics News Ardelyx News Oric Pharmaceuticals News Praxis Precision Medicines News Zymeworks News LENZ Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMP) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMMP Stock Alerts